IGA NEPHROPATHY
Clinical trials for IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise in slowing kidney disease progression
Disease control CompletedThis large, completed Phase 3 trial tested whether the drug iptacopan (LNP023) could help control IgA nephropathy, a serious kidney disease. The study involved 518 adults with confirmed disease who were already on standard care. Researchers compared iptacopan to a placebo to see …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 00:21 UTC
-
New drug tested for rare kidney diseases shows early safety profile
Disease control CompletedThis early-phase study tested the safety and effects of an experimental drug called ARO-C3. It involved 62 healthy volunteers and patients with two rare kidney diseases (C3G and IgA Nephropathy). The main goal was to see how the body processes the drug and to check for side effec…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New drug shows promise for slowing kidney damage
Disease control CompletedThis study tested whether HR19042 capsules could help people with IgA nephropathy, a kidney disease where protein leaks into urine. Researchers compared the capsules against placebo pills in 316 adults with confirmed kidney damage. The main goal was to see if the treatment could …
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug tested to protect kidneys from scarring disease
Disease control CompletedThis study tested whether adding the drug atrasentan helps control IgA nephropathy, a kidney disease that causes scarring, in patients already taking standard protective medications. Fifty-four adults with the disease tried atrasentan and a placebo in different orders to see whic…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Kidney biopsy guides fight against silent kidney killer
Disease control CompletedThis study tested whether adding steroid therapy to standard kidney-protecting medications works better for IgA nephropathy patients with severe kidney damage seen on biopsy. Researchers compared two treatment approaches over two years in 62 adults with this autoimmune kidney dis…
Matched conditions: IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC